Roger Sidhu

Panitumumab–FOLFOX4 Treatment and <i>RAS</i> Mutations in Colorectal Cancer

Jean‐Yves Douillard, Kelly S. Oliner, Salvatore Siena et al. · New England Journal of Medicine · 2013 · 2.2K citations · Full text

Medicine, Oncology, Pharmacology +15

Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study

Timothy Price, Marc Peeters, Tae Won Kim et al. · The Lancet Oncology · 2014 · 470 citations · Full text

Medicine, Oncology, Pharmacology +9

Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial

Daniel V.T. Catenacci, Niall C. Tebbutt, André M. Murad et al. · The Lancet Oncology · 2017 · 343 citations · Full text

Medicine, Oncology, Pharmacology +15

Analysis of <i>KRAS</i> / <i>NRAS</i> Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer

Marc Peeters, Kelly S. Oliner, Timothy Price et al. · Clinical Cancer Research · 2015 · 185 citations · Full text

Medicine, Oncology, Pharmacology +17

Mismatch repair protein MutL becomes limiting during stationary-phase mutation

Reuben S. Harris, Gang Feng, Kimberly J. Ross et al. · Genes & Development · 1997 · 156 citations · Full text

Life Sciences, Genetics, Microbiology +17